Amoéba (PAR: ALMIB) and Koppert have extended their distribution agreement for AXPERA-based biofungicides into orchards across 19 EU countries, moving the opportunity into the pre-commercialisation phase following initial co-development and field trials. The agreement covers crops including apples, pears and other orchard fruits and addresses nearly 600,000ha, including c 320,000ha of apple orchards and 80,000ha of pear orchards, with the companies ultimately targeting c 40% of cultivated acreage. Fruit production represents Europe’s fourth-largest fungicide market by value, accounting for approximately 10% of the European market, with growers typically spending €1,000–1,500/ha annually on fungal disease control. The expansion follows the July 2026 extension of the existing Koppert agreement covering vineyards and vegetable crops through June 2031 and supports Amoéba’s objective of €40m revenue by 2030.
Initial trials conducted on apple orchards across five European countries during summer 2026 demonstrated efficacy above 90% against apple scab and powdery mildew when AXPERA was used alongside conventional fungicides. A further trial campaign is planned for 2027 across apple and pear crops to confirm these results and evaluate additional treatment programmes, with commercial launch expected in 2029 subject to regulatory approvals. The agreement builds on the recent launches of AXPERA-based TIAGAN for vineyards and YAZU for vegetable crops and broadens the addressable market for Amoéba’s technology, although meaningful orchard revenues remain dependent on successful further trials, regulatory approval and commercialisation.
Industrials | Comment
Investment Companies | Comment
Industrials | Comment